Online inquiry

IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8899MR)

This product GTTS-WQ8899MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IGHE gene. The antibody can be applied in Chronic idiopathic urticaria research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NC_000014.9
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3497
UniProt ID P01854
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8899MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13601MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA R1450
GTTS-WQ1635MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ1682MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACZ885
GTTS-WQ14089MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-421
GTTS-WQ9169MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMGN-529
GTTS-WQ13798MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-10933
GTTS-WQ2028MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AHLX-20
GTTS-WQ11181MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI0562
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW